Development and Validation of PEG-PCL Based Nanoformulation of Rosiglitazone and Evaluation of its Brain Selectivity in Mice Model of Alzheimer’s disease
No Thumbnail Available
Date
2021-12
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Alzheimer's Association
Abstract
Type-2 Diabetes Mellitus and insulin resistance increases the risk of Alzheimer’s disease (AD). Recent studies highlighted the role of peroxisome proliferator-activated receptor-gamma (PPAR-γ) in modulation of AD. This study was designed to investigate the effect of rosiglitazone alone or in its nanoformulated form for an effective drug delivery in mice model of AD.
Description
Keywords
Pharmacy, Alzheimer’s disease, Rosiglitazone